Loncar Cancer Beta vs. Five Year Return

CNCR Etf  USD 13.74  0.45  3.17%   
Considering Loncar Cancer's profitability and operating efficiency indicators, Loncar Cancer Immunotherapy may not be well positioned to generate adequate gross income at the present time. It has a very high likelihood of underperforming in January. Profitability indicators assess Loncar Cancer's ability to earn profits and add value for shareholders.
For Loncar Cancer profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Loncar Cancer to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Loncar Cancer Immunotherapy utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Loncar Cancer's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Loncar Cancer Immunotherapy over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
The market value of Loncar Cancer Immuno is measured differently than its book value, which is the value of Loncar that is recorded on the company's balance sheet. Investors also form their own opinion of Loncar Cancer's value that differs from its market value or its book value, called intrinsic value, which is Loncar Cancer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Loncar Cancer's market value can be influenced by many factors that don't directly affect Loncar Cancer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Loncar Cancer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Loncar Cancer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Loncar Cancer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Loncar Cancer Immuno Five Year Return vs. Beta Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Loncar Cancer's current stock value. Our valuation model uses many indicators to compare Loncar Cancer value to that of its competitors to determine the firm's financial worth.
Loncar Cancer Immunotherapy is fourth largest ETF in beta as compared to similar ETFs. It is rated below average in five year return as compared to similar ETFs . Comparative valuation analysis is a catch-all technique that is used if you cannot value Loncar Cancer by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Loncar Five Year Return vs. Beta

Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Loncar Cancer

Beta

 = 

Covariance

Variance

 = 
0.93
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Five Year Return is considered one of the best measures to evaluate fund performance, especially from the mid and long term perspective. It shows the total annualized return generated from holding equity for the last five years and represents capital appreciation of the investment, including all dividends, losses, and capital gains distributions.

Loncar Cancer

Five Year Return

 = 

(Mean of Monthly Returns - 1)

X

100%

 = 
(8.20) %
Although Five Year Returns can give a sense of overall investment potential, it is recommended to compare equity performance with similar assets for the same five year time interval. Similarly, comparing overall investment performance over the last five years with the appropriate market index is a great way to determine how this equity instrument will perform during unforeseen market fluctuations.

Loncar Five Year Return Comparison

Loncar Cancer is currently under evaluation in five year return as compared to similar ETFs.

Beta Analysis

Loncar Cancer returns are very sensitive to returns on the market. As the market goes up or down, Loncar Cancer is expected to follow.

Loncar Cancer Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Loncar Cancer, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Loncar Cancer will eventually generate negative long term returns. The profitability progress is the general direction of Loncar Cancer's change in net profit over the period of time. It can combine multiple indicators of Loncar Cancer, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the funds index provider, as having a high strategic focus on the development of drugs that harness the bodys own immune system to fight cancer. Loncar Cancer is traded on NASDAQ Exchange in the United States.

Loncar Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Loncar Cancer. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Loncar Cancer position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Loncar Cancer's important profitability drivers and their relationship over time.

Use Loncar Cancer in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Loncar Cancer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Loncar Cancer will appreciate offsetting losses from the drop in the long position's value.

Loncar Cancer Pair Trading

Loncar Cancer Immunotherapy Pair Trading Analysis

The ability to find closely correlated positions to Loncar Cancer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Loncar Cancer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Loncar Cancer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Loncar Cancer Immunotherapy to buy it.
The correlation of Loncar Cancer is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Loncar Cancer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Loncar Cancer Immuno moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Loncar Cancer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Loncar Cancer position

In addition to having Loncar Cancer in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Broad Market ETFs Thematic Idea Now

Broad Market ETFs
Broad Market ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Market ETFs theme has 62 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Market ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Loncar Cancer Immuno is a strong investment it is important to analyze Loncar Cancer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Loncar Cancer's future performance. For an informed investment choice regarding Loncar Etf, refer to the following important reports:
Check out Trending Equities.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
To fully project Loncar Cancer's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Loncar Cancer Immuno at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Loncar Cancer's income statement, its balance sheet, and the statement of cash flows.
Potential Loncar Cancer investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Loncar Cancer investors may work on each financial statement separately, they are all related. The changes in Loncar Cancer's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Loncar Cancer's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.